Related Experiment Video

Updated: Mar 24, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K

Development of Liposomal Ciprofloxacin to Treat Lung Infections

David Cipolla1, Jim Blanchard2, Igor Gonda3

  • 1Aradigm Corp., Hayward, CA 94545, USA. cipollad@aradigm.com.

Pharmaceutics
|March 4, 2016
PubMed

Insights

Inhaled antibiotic treatments are lacking for many serious infections. Liposomal ciprofloxacin formulations show promise for improved delivery and efficacy against challenging pathogens.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Drug Delivery Systems

Background:

  • Limited approved inhaled antibiotic options exist beyond Pseudomonas aeruginosa in cystic fibrosis.
  • Inhaled antibiotics offer potential for high local concentrations and reduced systemic side effects.
  • Novel formulations are needed to address infections caused by tuberculosis, mycobacteria, fungi, and biowarfare agents.

Purpose of the Study:

  • To describe the development of liposomal ciprofloxacin formulations for inhaled delivery.
  • To highlight the potential benefits of liposomal formulations for treating respiratory infections.

Main Methods:

  • Development of two liposomal ciprofloxacin formulations: Lipoquin® and Pulmaquin®.
  • Focus on inhalation route for drug delivery.

Main Results:

  • Liposomal formulations may enhance tolerability and reduce dosing frequency.
  • Potential for improved penetration of biofilms and intracellular infections.
  • These formulations are under development by Aradigm Corporation.

Conclusions:

  • Liposomal ciprofloxacin represents a promising approach for inhaled antibiotic therapy.
  • Further development could address unmet needs in treating various respiratory pathogens.
Keywords:
bronchiectasisciprofloxacincystic fibrosisformulationinhalation deliveryliposomeslung infectionnon-tuberculous mycobacteria

More Related Videos

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.9K
Optical Screening of Novel Bacteria-specific Probes on Ex Vivo Human Lung Tissue by Confocal Laser Endomicroscopy09:24

Optical Screening of Novel Bacteria-specific Probes on Ex Vivo Human Lung Tissue by Confocal Laser Endomicroscopy

Published on: November 29, 2017

8.1K

Related Concept Videos

Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
18
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
614
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
761